Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.308 GBX | -5.64% | -9.66% | -34.68% |
Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
Apr. 03 | FTSE 100 up thanks to US economic data | AN |
Sales 2022 | 49K 61.4K | Sales 2023 | 55K 68.92K | Capitalization | 17.33M 21.72M |
---|---|---|---|---|---|
Net income 2022 | -4M -5.01M | Net income 2023 | -5M -6.27M | EV / Sales 2022 | 237 x |
Net cash position 2022 | 4.57M 5.73M | Net cash position 2023 | 2.36M 2.96M | EV / Sales 2023 | 272 x |
P/E ratio 2022 |
-3.18
x | P/E ratio 2023 |
-3.18
x | Employees | 43 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.93% |
1 day | -2.36% | ||
1 week | -6.51% | ||
Current month | +62.74% | ||
1 month | +75.76% | ||
3 months | -24.24% | ||
6 months | -39.81% | ||
Current year | -32.40% |
Managers | Title | Age | Since |
---|---|---|---|
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Chris Yates
BRD | Director/Board Member | 50 | 18-08-21 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 18-04-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.308 | -5.64% | 1 221 900 |
24-04-25 | 5.625 | -8.16% | 3,024,427 |
24-04-24 | 6.125 | +8.89% | 5,461,201 |
24-04-23 | 5.625 | -4.26% | 744,960 |
24-04-22 | 5.875 | 0.00% | 286,779 |
Delayed Quote London S.E., April 26, 2024 at 04:46 am EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.40% | 10.06M | |
-13.03% | 18.55B | |
-46.15% | 2.65B | |
+14.09% | 1.81B | |
-3.39% | 1.61B | |
+21.62% | 1.21B | |
-10.58% | 1.03B | |
-21.72% | 896M | |
-9.20% | 680M | |
-17.56% | 686M |
- Stock Market
- Equities
- EHP Stock